Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
Open Access
- 1 December 2015
- journal article
- review article
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 7, 157-167
Abstract
Fingolimod is a selective immunosuppressive agent approved worldwide for the treatment of relapsing-remitting multiple sclerosis (MS), a chronic and potentially disabling neurological condition. Randomized double-blind clinical trials have shown that fingolimod significantly reduces relapse rate and ameliorates a number of brain MRI measures, including cerebral atrophy, compared to both placebo and intramuscular interferon-1a. The effect on disability progression remains controversial, since one Phase III trial showed a significant benefit of treatment while two others did not. Although fingolimod has a very convenient daily oral dosing, the possibility of serious cardiac, ocular, infectious, and other rare adverse events justified the decision of the European Medicines Agency to approve the drug as a second-line treatment for MS patients not responsive to first-line therapy, or those with rapidly evolving course. In the United States, fingolimod is instead authorized as a first-line treatment. The aim of this review is to describe and discuss the characteristics of fingolimod concerning its efficacy, safety, and tolerability in the clinical context of multiple sclerosis management.Keywords
This publication has 84 references indexed in Scilit:
- Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisBrain, 2015
- A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedureBMC Pharmacology and Toxicology, 2015
- PML-IRIS during Fingolimod Diagnosed after Natalizumab DiscontinuationCase Reports in Neurological Medicine, 2014
- Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to NatalizumabEuropean Neurology, 2014
- Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisMultiple Sclerosis and Related Disorders, 2014
- Treatment of neuromyelitis optica: state-of-the-art and emerging therapiesNature Reviews Neurology, 2014
- Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawalMultiple Sclerosis Journal, 2012
- Fingolimod-associated macular edemaNeurology, 2012
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNature Reviews Drug Discovery, 2010
- FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and AustralasiaAmerican Journal of Transplantation, 2006